Lupin Limited — Q2 FY27 — November 4, 2026

1. Overall Tone of Management

Cautious. Management emphasized “steady performance,” diversified growth and confidence in longer-term strategy, but repeatedly acknowledged near-term pressure: intensifying US competition, expected declines in Tolvaptan and Mirabegron contributions, higher R&D and input costs, and margin moderation. The outlook is also more guarded than the prior year’s record-performance narrative: FY28 US revenue is expected to remain above $1 billion, but management did not commit to matching FY27.

2. Key Themes from Management Commentary

Growth remains broad, but not uniform. Q2 revenue grew 11% year over year; India grew 14.7% and other developed markets 46%, while emerging markets declined 4%. Organic growth was double-digit, excluding the US.
US business is in a transition from exclusivity-led gains to pipeline-led growth. Competition in Tolvaptan is increasing, Mirabegron competition is expected after September 2027, and management expects these products’ revenue and margin contribution to decline significantly.
Margins are holding near guidance, with headwinds ahead. Q2 EBITDA margin was 25.1%, but management maintained FY27 guidance of 24–25% and warned of moderation from US pricing pressure, R&D investment and Middle East-related input costs.
Complex products are central to the US strategy. Lupin aims to double the complex-product share of its US portfolio, with respiratory, injectables, biosimilars and 505(b)(2) products. Management plans more than 60 US launches over three years.
India is growing strongly, particularly in chronic therapies and diabetes. Chronic therapies grew 19.5%; diabetes grew over 25% for a third consecutive quarter. However, management acknowledged India’s growth relative to the market is not yet at its aspiration.
Developed markets, especially Europe, are becoming more important. Europe grew 45% year over year, and developed markets rose to 15% of revenue. Specialty ophthalmology is part of the expansion plan, including the Vigifarma acquisition and a licensing deal with Tenpoint.
Investment and capital allocation remain active. R&D was 7.9% of sales in Q2, with full-year spend expected around 8%. Management also described potential strategic acquisitions, particularly in specialty, while emphasizing disciplined deal selection.
Quality remediation remains unresolved. Pithampur Unit 2 remediation is “on track,” but management did not report a final resolution.

3. Q&A Analysis

US competition, Tolvaptan and gross margins

Questions: How do Tolvaptan and Mirabegron competition affect gross margins and US revenue? What competitor entries are expected?
Response: Tolvaptan had about 50% market share while Lupin was the sole generic, but management expects further competitors and a significant decline in both revenue and margin contribution, with pricing the larger impact. Mirabegron was described as relatively stable in Q2, with additional competition expected after September 2027.
Gross-margin resilience reflected mix in other markets and favorable FX forwards versus Q1, not the absence of product pressure. Management agreed that the FX benefit should unwind as the rupee stabilizes.
Signal: The answer was unusually direct on the downside: “we would expect the margin contribution and revenue contribution to come down significantly.”
Historical context: In Q2/Q3 FY26, Tolvaptan exclusivity and limited near-term competition were major growth drivers; by Q4 FY26, management had already incorporated competition into FY27 guidance. The current call makes the expected erosion more explicit.

US revenue outlook and replacement launches

Questions: Can FY28 US revenue match FY27? How should investors interpret FY27 guidance given H1 revenue of $683 million?
Response: FY27 US revenue guidance remains $1.1–1.2 billion. Management said the first half was above plan, but maintained guidance and would “see if we get any upside.” For FY28, the company expects $1 billion-plus, not necessarily a match to FY27. Tolvaptan pressure and later Mirabegron competition are expected to be partly offset by Apixaban, Dalbavancin and biosimilars. Management expects growth as more durable pipeline products contribute in FY29.
Signal: The answer preserved FY27 guidance despite apparent H1 outperformance, but offered no quantified FY28 range. The bridge from exclusivity products to replacement launches remains execution-dependent.
Historical context: FY26 US revenue was $1.3 billion, up about 40%. At Q4 FY26, management anticipated high-single- to low-double-digit erosion in FY27 while aiming to sustain a $1 billion-plus business.

Apixaban and 505(b)(2) commercialization

Questions: Could reimbursement or coverage delay uptake? What channels will Lupin target, and can margins and sales persist after generics enter?
Response: Apixaban oral suspension is expected to launch in Q1 FY28. Management said 505(b)(2) products require more commercial work than substitution generics, with additional investment over the next couple of quarters to develop market access and channel relationships. The strategy is targeted channels rather than direct-to-consumer. Management expects an attractive, “exclusive product” type margin and some retained share after generics enter, particularly in liquid-formulation channels.
Signal: Management acknowledged a gradual ramp (“a build-up over the months and quarters”) rather than immediate uptake. It did not quantify sales or share assumptions. The $10-billion-plus figure referred to the overall branded market, not Lupin’s addressable opportunity.

India growth and respiratory performance

Questions: What will drive acceleration to the 1.2–1.3x IPM growth target? Is respiratory weakness in inhalers or cough/cold?
Response: Management said India’s H1 prescription growth was 14.4% versus IPM growth of 14.3%, and admitted it was “not where we need to be.” Diabetes is strong; respiratory inhalation products (MDI, DPI, nebulization) were slower, while cough/cold products were strong. Management expects respiratory to pick up seasonally in H2 and cardiac to recover.
Signal: The response candidly acknowledged that current relative performance is short of its aspiration; the expected H2 improvement is not yet demonstrated.

Respiratory filing timelines and R&D spend

Questions: What is the status of Respimat and Ellipta filings? Could R&D be optimized?
Response: Exhibit batches are complete for Spiriva Respimat, with filing planned in FY27. Breo/Ellipta is expected to slip by a couple of months into Q1 of the next fiscal year; the broader target of 7–8 respiratory products remains on track within the fiscal year or shortly after. Management is reviewing R&D and expects to optimize some lines while protecting material programs, as investment shifts toward commercialization in specialty, biosimilars and 505(b)(2).
Signal: Ellipta’s timing has slipped from prior expectations. R&D optimization was acknowledged, but no future spending target was provided.

Biosimilars, capital deployment and other pipeline opportunities

Questions: What has Lupin learned from earlier biosimilar launches? What is the acquisition appetite? What are timelines for Teriparatide, Dulera and Diazepam nasal spray?
Response: Biosimilar success depends on payer incentives and substitution, not simply price cuts; management sees current US adoption as more favorable than five to eight years ago. It expects to file 4–5 US biosimilars over the next few years. On capital, management said specialty in Europe and the US is the first priority, with India also considered at appropriate valuations; leverage could reach 2.5x EBITDA if a compelling deal emerges. Teriparatide filing is expected later this fiscal year, with a first-wave opportunity in FY29. Diazepam is expected; Dulera depends on FDA queries and may launch next year or early FY29.
Signal: Management was clear that acquisitions are possible but conditional. Biosimilar revenue, market-share and launch economics remain unquantified.

4. Guidance / Outlook

Quantitative guidance

FY27 EBITDA margin: around 24–25%, maintained despite Q2 margin of 25.1%.
FY27 US revenue: $1.1–1.2 billion.
Second-half organic growth ex-US: around 20%.
FY27 R&D: around 8% of sales.
FY27 effective tax rate: around 27–28%.
India formulations: expected to grow 1.2–1.3x IPM; management also has a longer-term target to raise chronic therapies to 70% of the portfolio over five years.
US pipeline: more than 15 filings in FY27; over 60 launches over the next three years, including approximately 25 injectable and respiratory products, five biosimilars and 2–3 505(b)(2) products.
US outlook beyond FY27: at least $1 billion-plus in FY28; management expects growth as durable pipeline launches scale in FY29.
India pipeline: more than 80 launches over the coming year, supported by a sales force of nearly 11,400.

Qualitative signals

Margins are likely to moderate in coming quarters due to US competition, R&D investment and higher input costs.
US competition in Tolvaptan is expected to intensify further; Mirabegron competition is expected after September 2027.
FY28 may be a “period of consolidation,” despite longer-term potential for margins to recover toward 29–30% over time.
Additional commercial investment is planned for Apixaban and market access.
Management is exploring acquisitions, prioritizing specialty, with disciplined valuation thresholds.
No quantified new capex or hiring plan was given.

5. Standout Statements

“We would expect the margin contribution and revenue contribution to come down significantly.” — on Tolvaptan.
“The revenue should remain at a billion dollars plus” — FY28 US outlook, without committing to match FY27.
“H1, we are actually 16% ahead of the market, but definitely not where we need to be.” — India relative-growth ambition versus current delivery.
Apixaban uptake is expected to “be a build-up over the months and quarters.”
“The next year [is] a year of investment and building capabilities to build a more resilient business.”
Management said margins could reach 29–30% over time, while characterizing FY28 as potentially a consolidation year.

6. Red Flags / Positive Signals

Red flags
– Meaningful anticipated erosion in two important US products, with no quantified product-level bridge to replacement revenue.
– Gross-margin support from FX forwards is temporary; management agreed it should unwind.
– FY27 margin guidance is unchanged despite reported first-half performance above plan.
– India’s growth is strong in absolute terms, but H1 growth was only slightly ahead of IPM, below management’s stated aspiration.
– Ellipta/Breo filing has slipped; Pithampur Unit 2 remediation remains ongoing.
– Net cash fell to ₹3,349 crore from ₹4,636 crore at March 31, reflecting acquisition and dividend payments.

Positive signals
– Double-digit organic growth and broad contributions across India and developed markets.
– India chronic growth of 19.5%; diabetes growth exceeded 25% for a third consecutive quarter.
– Europe growth of 45% and developed markets’ share of revenue rising to 15%.
– Q2 EBITDA margin remained at 25.1% despite greater US competition.
– Large, increasingly complex US pipeline and tentative Apixaban approval.

7. Historical Comparison & Consistency Analysis

a. Quarter-by-Quarter Tone Evolution

Q2 FY26 — November 7, 2025

Dominant tone: Optimistic
Major themes this quarter:
Record results, with US exclusivity products and broad geographic growth.
Expansion of complex injectables and planned US biosimilar launches.
India chronic growth and expected first-wave Semaglutide opportunity.
VISUfarma acquisition and specialty expansion.
Tone shift vs previous quarter: N/A (baseline)

Q3 FY26 — February 13, 2026

Dominant tone: Optimistic
Major themes this quarter:
Record US sales and 14th consecutive quarter of company growth.
Pegfilgrastim approval and an expanding injectable/biosimilar pipeline.
India growth normalized for product exclusivity losses; chronic mix increased.
Higher margin guidance, despite expected Q4 moderation.
Tone shift vs previous quarter: No Change
What changed:
FY26 margin outlook was raised to 27–28% from earlier 25–26%.
Management remained confident that US revenue could stay above $1 billion, while more openly discussing the future impact of Tolvaptan and Mirabegron competition.

Q4 FY26 — May 8, 2026

Dominant tone: Optimistic
Major themes this quarter:
Record FY26 revenue and profitability; management said it had exceeded prior guidance.
US revenue reached $1.3 billion, supported by Tolvaptan and Mirabegron.
FY27 margin guidance reset lower to around 25%, with competition and higher R&D identified as pressures.
Specialty, biosimilars and VISUfarma positioned as longer-term growth drivers.
Tone shift vs previous quarter: No Change
What changed:
The narrative shifted from FY26 margin expansion to managing a lower FY27 margin base.
Management quantified the risk of high-single- to low-double-digit US revenue erosion, while relying on launches to offset it.
VISUfarma’s expected contribution and specialty ambitions became more prominent.

Q2 FY27 — November 4, 2026

Dominant tone: Neutral
Major themes this quarter:
Diversified growth, particularly in India and developed markets, offset by emerging-market weakness.
Increasing US price and share pressure in Tolvaptan; expected later Mirabegron competition.
Investment in complex US products, biosimilars, 505(b)(2)s and European specialty.
Margin guidance maintained, with explicit warning of moderation and FY28 consolidation.
Tone shift vs previous quarter: More Cautious
What changed:
Tolvaptan pressure moved from anticipated risk to an explicit expected “significant” decline in revenue and margin contribution.
FY28 US guidance became more conservative: $1 billion-plus, rather than a commitment to match FY27.
Management acknowledged India’s H1 outperformance versus IPM fell short of its own 20–30% ahead aspiration; Ellipta timing also slipped.

Trajectory Summary: Management’s tone progressed from optimism around record growth and US exclusivity in FY26 to more guarded expectations as those products face competition. The longer-term pipeline story is consistent, but the current call places greater emphasis on investment, margin moderation and the execution needed to replace US erosion.

b. Tracking Past Commitments vs Outcomes

FY27 US revenue above $1 billion: Prior calls anticipated sustaining $1 billion-plus; current FY27 guidance is $1.1–1.2 billion, with H1 revenue of $683 million. ✅ On track, though the full-year outcome remains pending.
FY27 EBITDA margin around 24–25%: Set in earlier calls and maintained now at 24–25%. ⏳ Pending; Q2’s 25.1% margin is consistent with the range, but FY27 is incomplete.
India formulations growth of 1.2–1.3x IPM: Repeatedly guided in prior calls. Current H1 prescription growth was 14.4% versus IPM growth of 14.3%; management admitted it is below its aspiration. ⏳ Not yet delivered.
VISUfarma acquisition and European expansion: Expected to close in FY26; current call cites Vigifarma and rising developed-market contribution. ✅ Acquisition completed, although current-call disclosure does not quantify progress against prior revenue targets.
Semaglutide-led India diabetes growth: Prior calls expected a first-wave launch and strong potential; current call reports 25%+ diabetes growth for a third consecutive quarter. ✅ Positive progress, though the company did not attribute all growth to Semaglutide.
Pithampur Unit 2 remediation: Management said it was addressing the issue in Q2 FY26 and remained on track in Q4 FY26. Current call says responses have been submitted and remediation is ongoing. ⏳ Delayed / unresolved.
Respimat and Ellipta filing schedule: Respimat work is progressing, with filing planned in FY27. Breo/Ellipta has slipped a couple of months into Q1 of the next fiscal year. ⏳ Ellipta delayed; Respimat remains on plan.
Pegfilgrastim commercial contribution: Earlier calls anticipated launch and meaningful contribution from FY27. The current call refers to biosimilar launches and expected contribution, but does not clearly confirm launch status or quantify revenue. ⏳ Progress unclear from this call.
US product pipeline: The three-year target increased from 50-plus products in Q4 FY26 to over 60 products now. ✅ Target expanded, with execution still ahead.

c. Narrative Shifts

The US story has shifted from exploiting exclusivity and rapid growth to replacing temporary product contributions with a broader pipeline.
Specialty in Europe, biosimilars and 505(b)(2) products are receiving more emphasis as durable-growth sources.
India chronic therapy remains a strategic priority, but the emphasis now includes meeting an ambition that current H1 performance has not yet reached.
Brazil, a major emerging-market growth driver in earlier calls, is now cited as a source of competition-related pressure.
Margin improvement is no longer the near-term narrative; management is emphasizing investment, stabilization and a longer-term recovery.

d. Consistency & Credibility Signals

Overall credibility: Medium. Management has consistently disclosed the major US competition risks and explained why FY27 margins are lower than FY26. It also raised FY26 guidance before reporting a record year. However, several growth and launch assumptions remain dependent on pipeline execution, Ellipta has slipped, Pithampur remediation is unresolved, and India’s outperformance target has not yet been achieved.

e. Evolution of Key Themes

US demand/revenue: Deteriorating near term. Tolvaptan competition is now active; Mirabegron competition is expected later. Pipeline replacements are promising but not yet proven at scale.
Margins: Deteriorating from FY26 peak; stable within FY27 guidance. Management expects moderation and a possible FY28 consolidation period.
India: Improving in absolute growth, mixed versus target. Chronic and diabetes performance is strong; relative outperformance versus IPM is modest in H1.
Developed markets/Europe: Improving. Strong growth and specialty expansion are increasing strategic importance.
Emerging markets: Deteriorating. Growth has slowed, with Brazil competition cited as a factor.
Quality/compliance: Stable but unresolved. Remediation continues without a reported final resolution.

f. Additional Insights

Lupin’s growth mix is becoming more diversified geographically, but near-term earnings remain exposed to US products whose economics are changing quickly.
Management’s confidence in eventual margin recovery rests on future launches and scale-up, while near-term US guidance already assumes meaningful erosion.
The company is shifting from a launch-count narrative toward a more commercial and access-intensive model—particularly for Apixaban and biosimilars—which could require higher spending before revenue builds.

Lupin Holds Margin Guidance as U.S. Competition Intensifies